Sight Sciences, Inc. (NASDAQ:SGHT) Insider Jeremy B. Hayden Sells 6,922 Shares

Sight Sciences, Inc. (NASDAQ:SGHT) insider Jeremy B. Hayden sold 6,922 shares of the company’s stock in a transaction dated Friday, January 17th. The stock was sold at an average price of $2.78, for a total value of $19,243.16. Following the completion of the transaction, the insider now directly owns 145,091 shares in the company, valued at approximately $403,352.98. The trade was a 4.55 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Sight Sciences Stock Performance

NASDAQ:SGHT opened at $2.89 on Wednesday. The firm has a market capitalization of $146.70 million, a PE ratio of -2.83 and a beta of 2.57. The company has a current ratio of 10.18, a quick ratio of 9.74 and a debt-to-equity ratio of 0.36. Sight Sciences, Inc. has a 1 year low of $2.67 and a 1 year high of $8.45. The firm’s fifty day simple moving average is $3.59 and its 200 day simple moving average is $5.35.

Sight Sciences (NASDAQ:SGHT) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.01. Sight Sciences had a negative return on equity of 47.28% and a negative net margin of 63.30%. The business had revenue of $20.16 million for the quarter, compared to analyst estimates of $20.41 million. On average, sell-side analysts anticipate that Sight Sciences, Inc. will post -1.01 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Arkadios Wealth Advisors bought a new position in Sight Sciences during the fourth quarter worth $47,000. SG Americas Securities LLC boosted its holdings in Sight Sciences by 47.6% in the 4th quarter. SG Americas Securities LLC now owns 17,622 shares of the company’s stock valued at $64,000 after purchasing an additional 5,681 shares during the period. The Manufacturers Life Insurance Company acquired a new stake in Sight Sciences in the 2nd quarter worth $95,000. GSA Capital Partners LLP bought a new position in shares of Sight Sciences during the 3rd quarter worth about $136,000. Finally, American Century Companies Inc. raised its position in shares of Sight Sciences by 31.1% during the second quarter. American Century Companies Inc. now owns 35,948 shares of the company’s stock valued at $240,000 after buying an additional 8,527 shares during the last quarter. 55.51% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

SGHT has been the subject of several recent research reports. Piper Sandler reissued a “neutral” rating and issued a $5.50 price target (down previously from $6.00) on shares of Sight Sciences in a research note on Friday, November 8th. Morgan Stanley decreased their target price on shares of Sight Sciences from $7.00 to $5.00 and set an “equal weight” rating for the company in a research report on Monday, November 11th. UBS Group initiated coverage on shares of Sight Sciences in a report on Friday, December 6th. They set a “buy” rating and a $5.50 price target on the stock. Needham & Company LLC reiterated a “hold” rating on shares of Sight Sciences in a report on Tuesday, January 14th. Finally, Lake Street Capital cut their target price on Sight Sciences from $5.00 to $3.00 and set a “hold” rating on the stock in a report on Wednesday, January 15th. Five research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $4.72.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.